Last reviewed 2026-05-23 · How we verify

Atrican (TENONITROZOLE)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 24/100

Atrican (generic name: TENONITROZOLE) is a tenonitrozole drug. It is currently in Phase 2 development for Infection by Trichomonas.

African works by targeting the parasite that causes Trichomonas infections.

Atrican is a small molecule with the synonyms ATRICAN, TENONITROZOL, TENONITROZOLE, and TENONITROZOLE.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TENONITROZOLE
Drug class	tenonitrozole
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of African like a key that fits into a lock on the parasite's cell. When it binds, it disrupts the parasite's ability to multiply and cause infection. This helps the body's immune system fight off the infection more effectively.

Approved indications

Infection by Trichomonas

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Atrican CI brief — competitive landscape report
Atrican updates RSS · CI watch RSS

Frequently asked questions about Atrican

What is Atrican?

Atrican (TENONITROZOLE) is a tenonitrozole drug, indicated for Infection by Trichomonas.

How does Atrican work?

African works by targeting the parasite that causes Trichomonas infections.

What is Atrican used for?

Atrican is indicated for Infection by Trichomonas.

What is the generic name of Atrican?

TENONITROZOLE is the generic (nonproprietary) name of Atrican.

What drug class is Atrican in?

Atrican belongs to the tenonitrozole class. See all tenonitrozole drugs at /class/tenonitrozole.

What development phase is Atrican in?

Atrican is in Phase 2.

Drug class: All tenonitrozole drugs
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Infection by Trichomonas

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing